FENC

SEC filing FENC Presents New PEDMARK Research at 2026 ASCO, Shows Safe Use in AYA and Adult Populations, +Significant Reduction in Cisplatin-Induced Ototoxicity

10d ago

News Fennec Q2 Sales Jump 33 Percent

14d ago

SEC filing FENC Grants 50,000 Stock Options to New Employees at $9.75 Exercise Price with 3-Year Vesting Period

14d ago

News Fennec Pharmaceuticals GAAP EPS of $0.01 beats by $0.04, revenue of $15.11M beats by $1.27M

19d ago

Insider trade Sale by Chris A Rallis

20d ago

Insider trade Sale by Rosty Raykov

31d ago

SEC filing FENC Retires Raykov, Shrinks Board to 5, No Vacancies Post-Annual Meeting

34d ago

SEC filing FENC Reports $44.6M Net Product Sales, +50% YoY; $13.8M Q4 Sales, +75% YoY; $42M Oversubscribed Equity Offering; Positive Japan Study Topline; Conference Call 8:30 a.m. ET

69d ago

SEC filing FENC Announces PEDMARK ® Collaboration with TGH Cancer Institute for Real-World Ototoxicity Study in AYA and Adult Patients with Cisplatin Tumors

89d ago

Insider trade Sale by Rosty Raykov

90d ago

News United Airlines selects GE Aerospace (GE)’s GEnx Engines for Boeing 787

96d ago

Insider trade Sale by Rosty Raykov

104d ago

News Warsh Call for New Fed-Treasury Accord Unsettles Bond Market

112d ago

Scanner Unusual volume (z=6.5)

169d ago

Scanner Unusual volume (z=6.5)

170d ago

Scanner Unusual volume (z=6.5)

171d ago